Soleno Therapeutics (SLNO) Other Non-Current Liabilities (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Other Non-Current Liabilities data on file, last reported at $1.4 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1.4 million, down 91.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (down 91.98% YoY), and the FY2025 annual result was $525000.0, down 96.45% from the prior year.
• Other Non-Current Liabilities grew to $1.4 million in Q1 2026 per SLNO's latest filing, from $525000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $19.5 million in Q3 2025 and troughed at $271000.0 in Q2 2025.
• A 5-year average of $10.1 million and a median of $9.4 million in 2023 frame the typical range for Other Non-Current Liabilities.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 48.6% in 2025 and fell as far as 98.01% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $8.8 million in 2022, then soared by 30.72% to $11.5 million in 2023, then gained by 28.07% to $14.8 million in 2024, then plunged by 96.45% to $525000.0 in 2025, then jumped by 171.43% to $1.4 million in 2026.
• Business Quant data shows SLNO's Other Non-Current Liabilities at $1.4 million in Q1 2026, $525000.0 in Q4 2025, and $19.5 million in Q3 2025.